10-Q: Silexion Therapeutics Reports Losses in Q2 2024 Amidst Ongoing Clinical Trials

Silexion Therapeutics, a clinical-stage biotechnology company, reported increased net losses for the second quarter of 2024 as it continues to invest heavily in the research and development of its lead pancreatic cancer treatment candidate, SIL-204B.

Summary

• Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers.
• The company's lead product candidate, SIL-204B, is a treatment for locally advanced pancreatic cancer.
• Silexion reported a net loss of $1.5 million for Q2 2024 and $2.9 million for the six months ended June 30, 2024.
• Research and development expenses decreased by $0.4 million to $0.8 million in Q2 2024 compared to Q2 2023, mainly due to a decrease in subcontractor expenses.
• General and administrative expenses increased by $0.4 million to $0.6 million in Q2 2024 compared to Q2 2023, primarily due to higher payroll and professional services costs.
• As of June 30, 2024, Silexion had $1.7 million in cash and cash equivalents.
• The company completed a business combination with Moringa Acquisition Corp on August 15, 2024, and is now listed on the Nasdaq Global Market.
• Silexion expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its clinical trials and seeks regulatory approvals.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's significant losses, low cash reserves, and the going concern warning. However, the recent business combination, PIPE financing, and ELOC agreement provide some positive signals, preventing an even lower score.

Positives

• Completed business combination with Moringa Acquisition Corp, providing access to public markets and potential funding.
• Secured $2.0 million in PIPE financing, providing immediate capital.
• Established an equity line of credit (ELOC) agreement for up to $15.0 million, offering potential future funding.
• The company has a clear focus on developing treatments for KRAS-driven cancers, a significant unmet medical need.
• Received $5.8 million in grants from the Israeli Innovation Authority, validating the company's technology and providing non-dilutive funding.

Negatives

• The company has a history of significant operating losses, with an accumulated deficit of $29.7 million as of June 30, 2024.
• Reported a net loss of $2.9 million for the six months ended June 30, 2024.
• Cash and cash equivalents were only $1.7 million as of June 30, 2024.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company will need to raise substantial additional funding to continue operations and advance its clinical trials.

Risks

• Silexion has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company will need to raise significant additional capital to fund operations, which may not be available on acceptable terms or at all.
• Clinical trials are expensive, time-consuming, and uncertain, and Silexion may never generate the necessary data or results required to obtain marketing approval.
• Even if approved, Silexion's product candidates may not achieve commercial success.
• Reliance on the ELOC or other equity financings could result in significant dilution to existing shareholders and may adversely affect the market price of the company's shares.
• The ongoing conflict between Israel and Hamas could potentially disrupt the company's operations, although no material impact has been reported to date.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances the development of SIL-204B, initiates pre-clinical and clinical trials, and seeks regulatory approvals. They anticipate increased spending on research and development, as well as general and administrative expenses associated with operating as a public company.

Management Comments

• Our management evaluated, with the participation of our chief executive officer and chief financial officer, whom we refer to as our Certifying Officers, the effectiveness of our disclosure controls and procedures as of June 30, 2024, pursuant to Rule 13a-15(b) or Rule 15d-15(b) under the Exchange Act.
• Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2024.

Industry Context

Silexion Therapeutics is operating in the highly competitive biotechnology industry, specifically within the oncology segment. The focus on KRAS-driven cancers places them in a niche with significant unmet medical needs but also intense research and development efforts by numerous companies. The company's approach using RNA interference therapeutics is a relatively novel and complex area, with both high potential and significant challenges.

Comparison to Industry Standards

• Many biotechnology companies, such as Moderna and Alnylam Pharmaceuticals, are developing RNA-based therapies, but Silexion's focus on KRAS-driven cancers and local administration differentiates it.
• Compared to industry standards, Silexion's financial metrics are typical for a clinical-stage biotechnology company with no approved products. For example, Alnylam Pharmaceuticals, a leader in RNAi therapeutics, reported a net loss of $900 million in 2023, while Moderna, another leader in RNA-based therapies, reported a net loss of $4.7 billion in 2023.
• Silexion's reliance on grants and equity financing is also common in the industry. Many companies at this stage, such as CRISPR Therapeutics and Intellia Therapeutics, rely on similar funding models.
• Silexion's progress in clinical trials will be a key determinant of its success compared to competitors like Mirati Therapeutics and Amgen, both of which have KRAS inhibitors in later stages of development or on the market.

Corporate Governance

Related Party Transactions

• The company issued warrants to related parties (shareholders and directors) to purchase preferred shares.
• As of June 30, 2024, $321 was due to related parties for warrants to preferred shares.
• The company engaged in transactions with related parties, including share-based compensation and financial expenses.
• The controlling stakeholder of the Sponsor is entitled to a gross monthly fee of $10 for a period of 36 months following closing under the A&R BCA.

Stakeholder Impact

• Shareholders: Existing shareholders may face significant dilution due to potential future equity financings, including the ELOC.
• Employees: The company's ability to continue operations and retain employees depends on securing additional funding.
• Customers: The company does not currently have any customers as it is still in the clinical development stage.
• Suppliers: The company's ability to pay suppliers may be impacted if it fails to secure additional funding.
• Creditors: The company has outstanding debt obligations, including the EarlyBird Convertible Note and the A&R Sponsor Promissory Note.

Next Steps

• Apply for Orphan Drug Designation in both the U.S. and EU for SIL-204B.
• Initiate a clinical trial powered for statistical significance with respect to SIL-204B.
• Initiate toxicological studies with respect to SIL-204B.
• Seek marketing approvals for SIL-204B in various territories.
• Continue research and development efforts to utilize the company's technology as a platform for silencing the KRAS oncogene.
• Secure additional funding through the ELOC, public or private equity offerings, debt financings, or other strategic transactions.

Key Dates

Keywords

KRAS, oncology, pancreatic cancer, siRNA, RNA interference, clinical trials, biotechnology, drug development, cancer treatment, precision medicine